Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−176.94 M USD
14.09 M USD
50.16 M
About NewAmsterdam Pharma Company N.V.
Sector
CEO
Michael H. Davidson
Headquarters
Naarden
Website
Founded
2022
ISIN
NL00150012L7
FIGI
BBG01BNNTQN4
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NAMS is 25.95 USD — it has increased by 1.25% in the past 24 hours. Watch NewAmsterdam Pharma Company N.V. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NewAmsterdam Pharma Company N.V. stocks are traded under the ticker NAMS.
NAMS stock has risen by 5.92% compared to the previous week, the month change is a 28.08% rise, over the last year NewAmsterdam Pharma Company N.V. has showed a 130.26% increase.
We've gathered analysts' opinions on NewAmsterdam Pharma Company N.V. future price: according to them, NAMS price has a max estimate of 50.00 USD and a min estimate of 30.00 USD. Watch NAMS chart and read a more detailed NewAmsterdam Pharma Company N.V. stock forecast: see what analysts think of NewAmsterdam Pharma Company N.V. and suggest that you do with its stocks.
NAMS reached its all-time high on Nov 23, 2022 with the price of 32.88 USD, and its all-time low was 5.63 USD and was reached on Oct 26, 2023. View more price dynamics on NAMS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NAMS stock is 3.05% volatile and has beta coefficient of 1.22. Track NewAmsterdam Pharma Company N.V. stock price on the chart and check out the list of the most volatile stocks — is NewAmsterdam Pharma Company N.V. there?
Today NewAmsterdam Pharma Company N.V. has the market capitalization of 2.74 B, it has decreased by −3.68% over the last week.
Yes, you can track NewAmsterdam Pharma Company N.V. financials in yearly and quarterly reports right on TradingView.
NewAmsterdam Pharma Company N.V. is going to release the next earnings report on Mar 28, 2025. Keep track of upcoming events with our Earnings Calendar.
NAMS earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.50 USD resulting in a 63.94% surprise. The estimated earnings for the next quarter are −0.51 USD per share. See more details about NewAmsterdam Pharma Company N.V. earnings.
NewAmsterdam Pharma Company N.V. revenue for the last quarter amounts to 29.11 M USD, despite the estimated figure of 1.87 M USD. In the next quarter, revenue is expected to reach 1.73 M USD.
NAMS net income for the last quarter is −16.65 M USD, while the quarter before that showed −39.01 M USD of net income which accounts for 57.32% change. Track more NewAmsterdam Pharma Company N.V. financial stats to get the full picture.
No, NAMS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 29.00 employees. See our rating of the largest employees — is NewAmsterdam Pharma Company N.V. on this list?
Like other stocks, NAMS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NewAmsterdam Pharma Company N.V. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NewAmsterdam Pharma Company N.V. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NewAmsterdam Pharma Company N.V. stock shows the strong buy signal. See more of NewAmsterdam Pharma Company N.V. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.